yemenjmedYemen Journal of MedicinecoVolume 3 Issue 2MultidisciplinaryEnglishMay-August 2024NNY20240911ArticleSurvodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative reviewEnglishY97101Abdelmoneim B. Yousif1EnglishNEbtihal AbdelmoneimHassan2EnglishYMohamed FawziMudarres3EnglishYMusaab FahmiYousef4EnglishY EnglishY10.18231/j.yjom.2024.005The global increase in type 2 diabetes mellitus (T2DM) and obesity requires effective treatments. However, conventional antidiabetic drugs often result in weight gain, highlighting the need for novel therapies that treat both T2DM and obesity. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs have been shown to be effective in weight loss and metabolic improvement. Survodutide (BI 456906) is an investigational long-acting double agonist administered weekly. Phase 2 trials exhibited significant reductions in HbA1c (up to 1.7% at 16 weeks) and substantial weight loss (up to 14.9% at 46 weeks) in patients with T2DM and obesity. In addition, survodutide enhanced cardiovascular risk factors and some markers of non-alcoholic steatohepatitis (NASH). However, notable rates of gastrointestinal side effects and treatment discontinuation have been observed. Future research should prioritize addressing these adverse effects and assessing long-term outcomes. The current review evaluated the efficacy and safety of survodutide, a novel dual GLP-1/GIP receptor agonist, in managing obesity and T2DM. Clinical and preclinical data on survodutide were analyzed, focusing on its mechanism of action, clinical trial results, and comparisons with other therapies.EnglishSurvodutide, Weight Loss, Type 2 Diabetes Mellitus, Obesity, Glycemic Control, Dual Agonist Therapy 1https://www.yemenjmed.com/admin/abstract?id=110References16191.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Grant B, Sandelson M, Agyemang-Prempeh B, Zalin A. Managing obesity in people with type 2 diabetes. Clinical medicine (London, England). 2021;21(4):e327-e231.2.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Roomy MA, Hussain K, Behbehani HM, Abu-Farha J, Al-Harris R, Ambi AM, et al. Therapeutic advances in obesity management: an overview of the therapeutic interventions. Frontiers in endocrinology. 2024;15:1364503.3.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Zealandpharma. Survodutide zealandpharma: zealandpharma; 2024 [Available from: https://www.zealandpharma.com/pipeline/survodutide/4.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The lancet Diabetes and;amp; endocrinology. 2024;12(3):162-73.5.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Pocai A. Action and therapeutic potential of oxyntomodulin. Molecular metabolism. 2014;3(3):241-51.6.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Klein T, Augustin R, Hennige AM. Perspectives in weight control in diabetes - Survodutide. Diabetes research and clinical practice. 2024;207:110779.7.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular metabolism. 2022;66:101633.8.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Jungnik A, Arrubla Martinez J, Plum-Mand;ouml;rschel L, Kapitza C, Lamers D, Thamer C, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, obesity and;amp; metabolism. 2023;25(4):1011-23.9.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Bland;uuml;her M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470-82.10.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Thomas L, Martel E, Rist W, Uphues I, Hamprecht D, Neubauer H, et al. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes, obesity and;amp; metabolism. 2024;26(6):2368-78.11.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; NLM. A phase 2 Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. 2022-2024.12.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of obesity and;amp; metabolic syndrome. 2023;32(1):25-45.13.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Frand;iacute;as JP, Davies MJ, Rosenstock J, Pand;eacute;rez Manghi FC, Fernand;aacute;ndez Landand;oacute; L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine. 2021;385(6):503-15.14.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Venniyoor A. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022;387(15):1433-4.15.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2023;402(10402):613-26.16.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Ruder K. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide. Jama. 2024;331(1):9-11.17.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Bisson A, Fauchier G, Fauchier L. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. The New England journal of medicine. 2023;389(17):1628.18.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A. Obesity: a gender-view. Journal of Endocrinological Investigation. 2024;47(2):299-306.19.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; NLM. A Phase III Clinical Trial to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZEand;trade; - CVOT). [Clinical Trial]. In press 2023 and;ndash; 2024.and;nbsp;Available from: https://www. centerwatch.com/clinical-trials/listings/NCT06077864/a-study-totest-the-effect-of-survodutide-bi-456906-on-cardiovascular-safetyin-people-with-overweight-or-obesity-synchronizetm-cvot.20.and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp;and;nbsp; Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? International journal of obesity (2005). 2024. Available from:and;nbsp;from: https://pubmed.ncbi.nlm.nih.gov/38302593/.